Hematologic malignancies: From clinical science to clinical practice - 2nd European Congress. 24-26 February 2006, Barcelona, Spain

Therapeutic progress in the management of lymphoproliferative disorders suggest a promising impact on survival and quality of life for patients. Several relevant developments in diagnosis, prognosis, lymphomagenesis and treatment of these malignancies are currently being reported, and more related literature is being published. A considerable number of clinical trials are underway to evaluate the activity, tolerability and efficacy of new drugs and strategies. Critical themes in current research include biological and molecular aspects related to diagnosis, prognosis and treatment of lymphoma, drug delivery, pharmacokinetics, the definition of new therapeutic targets, costs and establishment of new in vivo models for the selection of active drugs. Experts participating in the 2nd European Congress on Hematologic Malignancies underlined the current interest in new therapies that are focused on monoclonal antibodies and radioimmunotherapy, and the interest in drugs that target the vascular and immune systems.